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Background: Cardiomyopathy is a progressive myocardial disorder. Here, we attempted to reveal the possible
mechanism of cardiomyopathy at the transcription level with the roles of microRNAs (miRNAs) and transcription
factors (TFs) taken into account.
Method: We firstly identified differentially expressed genes (DEGs) between cardiomyopathy patients and controls
with data from the gene expression omnibus (GEO) database. DEGs were associated with the canonical pathways,
molecular and cellular functions, physiological system development and function in the Ingenuity Knowledge Base
by using the Ingenuity Pathway Analysis (IPA) software. TFs and miRNAs that DEGs significantly enriched were
identified and a double-factor regulatory network was constructed.
Results: A total of 1,680 DEGs were identified. The DEGs were enriched for various pathways, with glucocorticoid
receptor signaling as the most significant. A double-factor regulatory network was constructed, including seven TFs
and two miRNAs. A subnetwork under the regulation of MEF2C and SRF was also constructed to illustrate their
regulatory effects on cardiac functions.
Conclusion: Our results may provide new understanding of cardiomyopathy and may facilitate further therapeutic
studies.
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Cardiomyopathy is a progressive myocardial disorder, usu-
ally leading to cardiovascular death or heart failure-related
disability [1]. It develops at any age, in either sex, and in
any population [2,3]. The etiology of cardiomyopathy is
highly complex and improving its treatments has become
a research hotspot.
Using bioinformatics combined with gene expression
data to identify potential therapeutic targets has shown
great application prospects. The majority of the previous
studies mainly focused on the analyses of differentially
expressed genes (DEGs), without considering microRNAs
(miRNAs) and transcription factors (TFs) that regulate the
expression of DEGs. miRNAs are small non-coding RNAs
that control various biological processes through affecting* Correspondence: xawanglei@163.com
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unless otherwise stated.the stability and translation of target mRNAs. Previous
studies have proposed several miRNAs as being involved
in the pathogenesis of cardiomyopathy, such as miR-1 [4]
and miR-21 [5]. TFs can regulate gene expression through
binding to the cis-elements in target genes’ promoter
regions. TFs, such as MEF2, have been reported to be
associated with cardiomyopathy [6]. Considering the
important regulatory roles of miRNAs and TFs in the
pathogenesis of cardiomyopathy, identification of miRNAs
and TFs that enriched with target DEGs and construc-
tion of a double-factor regulatory network may provide
new understanding of the molecular mechanism of
cardiomyopathy.
In the current study, based on gene expression data
from the Gene Expression Omnibus (GEO) database, we
acquired DEGs, miRNAs and TFs that enriched with target
DEGs and constructed a double-factor regulatory network.td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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myopathy at the transcription level.
Methods
Ethics Statement
This study was approved by the institutional review
board of the Xi’an Children’s Hospital (20140518).Figure 1 Ingenuity Pathway Analysis results. The significant canonical pathWritten informed consent was obtained from all patients
for the publication of this report and any accompanying
images.
Microarray data
The gene expression profile GSE5406 from the GEO
database was used. This dataset includes transcriptionways in which differently expressed genes (DEGs) were enriched are shown.
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194 of which were from patients with advanced cardio-
myopathy and 16 of which were from healthy donors.
All patients had New York Heart Association class 3 to
4 symptoms and left ventricular systolic dysfunction,
with ejection fraction of 14 ± 8% (mean ± SD). Patients
suffered from heart failure due to ischemic (n =86) or
idiopathic dilated (n =108) cardiomyopathy. Control sam-
ples had normal left ventricular function with ejection
fraction of 56 ± 7% (P =0.0001 versus patients). None
of the subjects received mechanical support with left
ventricular assist devices. Myocardial tissue samples
were obtained from patients undergoing heart trans-
plantation and from controls deemed unsuitable for
transplantation. Whole hearts were removed after preser-
vation in cold cardioplegia at the time of transplantation
or donor harvest. Then, segments of noninfarcted left
ventricular free wall were snap-frozen in liquid nitrogen.
For each sample, RNA was isolated by using Trizol
reagent (Invitrogen, Carlsbad, CA, USA). The dataset
was generated by using the (HG-U133A) Affymetrix
Human Genome U133A Array (Affymetrix, Santa Clara,
CA, USA).
Identification of differentially expressed genes (DEGs)
Raw data from all arrays were normalized using Robust
Multi-array Analysis (RMA) [7] in the R software (version
3.0.0). The resulting expression values were used to
identify DEGs with the limma package (3.12.1) in R.
DEGs were detected by using t-tests and multiple test cor-
rections were carried out with the Benjamini-Hochberg
method [8]. The threshold for significance was set as
P <0.01.
Enrichment analysis
To explore the functions and pathways of DEGs, DEGs
were associated with the canonical pathways, molecularTable 1 Ingenuity Pathway Analysis: functions related to diffe
Name P
Molecular and Cellular Functions
Cell Death and Survival 2




Physiological System Development and Function




Connective Tissue Development and Function 8and cellular functions, physiological system development
and function in the Ingenuity Knowledge Base by using
the Ingenuity Pathway Analysis (IPA) software (Ingenuity®
Systems, http://www.ingenuity.com).
Construction of miRNA-TF regulatory network
We also acquired miRNAs and TFs which were overrep-
resented with target DEGs. For miRNA analysis, we used
Targetscan [9], miRanda [10] and Pita [11] for miRNA
target DEGs prediction. To avoid false positive results,
miRNA-DEG prediction results supported by all three
prediction methods were considered to be confidential.
For TF analysis, we obtained TF binding sites and the
coordinate’s position information of human being from
the University of California Santa Cruz (UCSC) data-
base. TFs and miRNAs that DEGs significantly enriched
were identified by using the hypergeometric distribution
test. P <0.01 was set as the threshold. Based on the regu-
latory relationship between miRNAs or TFs and DEGs, a
network was constructed by using the IPA software.
Results
A total of 1,680 DEGs were identified, including 963
down-regulated genes and 717 up-regulated ones in ad-
vanced cardiomyopathy patients.
As shown in Figure 1, the IPA results of canonical
pathways showed that the DEGs were enriched for
various pathways, among which glucocorticoid recep-
tor signaling was the most significant. Molecular and
cellular functions analysis revealed that ‘Cell Death
and Survival’ (P =2.53 × 10−24 to 1.36 × 10−3) was the
top molecular function affected by DEGs followed by
‘Cellular Growth and Proliferation’ (P =3.37 × 10−24 to
1.36 × 10−3) (Table 1). ‘Cardiovascular System Develop-
ment and Function’ (P =4.17 × 10−12 to 1.20 × 10−3)
was the top physiological function mediated by DEGs
(Table 1).rentially expressed genes
-value Number of molecules
.53 × 10−24 to 1.36 × 10−3 405
.37 × 10−24 to 1.36 × 10−3 414
.41 × 10−13 to 1.36 × 10−3 236
.14 × 10−11 to 1.20 × 10−3 247
.13 × 10−10 to 1.36 × 10−3 328
.17 × 10−12 to 1.20 × 10−3 125
.96 × 10−11 to 1.22 × 10−3 92
.68 × 10−8 to 1.22 × 10−3 163
.84 × 10−7 to 1.20 × 10−3 117
.52 × 10−6 to 1.24 × 10−3 40
Figure 2 The microRNA (miRNA) and transcription factor (TF) regulato
semicircle. Up-regulated genes are shown in red and down-regulated gene
Table 2 Transcription factors and microRNAs (miRNAs)
enriched with target differentially expressed genes (DEGs)
Name P-value
MicroRNA
miR-30c-5p (and other miRNAs w/seed GUAAACA) 3.12 × 10−4
miR-125b-5p (and other miRNAs w/seed CCCUGAG) 2.15 × 10−3
Transcription factors
MEF2C 5.65 × 10−6
GATA1 6.11 × 10−5
SRF 1.53 × 10−4
NUPR1 4.18 × 10−4
ATF4 7.25 × 10−4
RELA 9.35 × 10−3
GLI2 1.42 × 10−2
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listed in Table 2. A network was constructed to illustrate
the regulatory relationships (Figure 2). Considering the
important role of SRF and MEF2C in the progression of
cardiomyopathy, a subnetwork under their regulation
was constructed and the biological functions they may
affect were also indicated (Figure 3).
Discussion
In the current study, based on GSE5406 from the GEO data-
base, 1,680 DEGs were identified between advanced cardio-
myopathy patients and healthy controls. DEGs were mapped
into the Ingenuity Knowledge Base and several canonical
pathways were screened out, with glucocorticoid receptor
signaling as the most significant. Glucocorticoid receptors
are involved in cardiovascular homeostasis [12] and
glucocorticoid could protect rodent hearts from ische-
mia/reperfusion injury [13]. Our results confirmed the
essential roles of this pathway in the pathogenesis of cardio-
myopathy. Molecular and cellular functions analysis revealedry network. TFs are shown with ellipse and miRNAs are shown with
s are shown in green.
Figure 3 The network under the regulation of SRF and MEF2C. Up-regulated genes are shown in red and down-regulated genes are shown
in green. The related cardiac functions are indicated in long ellipses.
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http://www.eurjmedres.com/content/19/1/57that ‘Cell Death and Survival’ (P =2.53 × 10−24 to 1.36 × 10−3)
was the top molecular function affected by DEGs, suggesting
that dysregulation of the cell function may contribute to the
progressive heart failure induced by cardiomyopathy.
TFs or miRNAs that DEGs significantly enriched were
identified and a double-factor regulatory network was
constructed, including seven TFs and two miRNAs
(Figure 2). All these miRNAs and TFs have previously
been implicated in cardiomyogenesis or cardiac func-
tion. Considering their important regulatory roles in
controlling various biological processes, these miRNAs
and TFs may provide new avenues for the therapeutic
strategies of cardiomyopathy. In addition, since all these
miRNAs and TFs were detected in patients suffered from
New York Heart Association class 3 to 4 symptoms, they
may also be considered as prognosis markers in clinicalpractice. A subnetwork under the regulation of SRF and
MEF2C was also constructed and the functions they may
affect were also indicated (Figure 3) considering the
considerable evidence in support of their involvement
in cardiomyopathy [14-17]. As shown in Figure 3, both
SRF and MEF2C may inhibit the expression of MYH6
and CNN1. MYH6 is a famous cardiac muscle myosin
gene and mutations of this gene are implicated in cardio-
myopathy in various studies [18]. Inhibition of CNN1 ex-
pression may disrupt its suppression of cardiomyopathy
through the εPKC pathway [19]. In addition, both SRF and
MEF2C may regulate the expression of NPPA, which
was overexpressed in patients in our results. This gene
is involved in many cardiac dysfunctions (Figure 3), in-
cluding myocardial infarction, heart failure, and high
ventricular pressure [20,21].
Wang et al. European Journal of Medical Research 2014, 19:57 Page 6 of 6
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In summary, with DEGs identified by gene chip data
generated by high-throughput technologies from the GEO
database, we constructed a cardiomyopathy double-factor
regulatory network and revealed the possible mechanism
on regulation level. A subnetwork under the regulation of
SRF and MEF2C was also constructed to illustrate their
possible regulatory roles. Our results may facilitate further
therapeutic studies of cardiomyopathy.
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